512 related articles for article (PubMed ID: 30179225)
21. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
22. Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition.
Mishima S; Taniguchi H; Akagi K; Baba E; Fujiwara Y; Hirasawa A; Ikeda M; Maeda O; Muro K; Nishihara H; Nishiyama H; Takano T; Tsuchihara K; Yatabe Y; Kodera Y; Yoshino T
Int J Clin Oncol; 2020 Feb; 25(2):217-239. PubMed ID: 31286289
[TBL] [Abstract][Full Text] [Related]
23. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
Bregar A; Deshpande A; Grange C; Zi T; Stall J; Hirsch H; Reeves J; Sathyanarayanan S; Growdon WB; Rueda BR
Gynecol Oncol; 2017 Jun; 145(3):446-452. PubMed ID: 28347512
[TBL] [Abstract][Full Text] [Related]
24. DeltaMSI: artificial intelligence-based modeling of microsatellite instability scoring on next-generation sequencing data.
Swaerts K; Dedeurwaerdere F; De Smet D; De Jaeger P; Martens GA
BMC Bioinformatics; 2023 Mar; 24(1):73. PubMed ID: 36859168
[TBL] [Abstract][Full Text] [Related]
25. Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients.
Duffy MJ; Crown J
Clin Chem; 2019 Oct; 65(10):1228-1238. PubMed ID: 31315901
[TBL] [Abstract][Full Text] [Related]
26. Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers.
Salem ME; Puccini A; Grothey A; Raghavan D; Goldberg RM; Xiu J; Korn WM; Weinberg BA; Hwang JJ; Shields AF; Marshall JL; Philip PA; Lenz HJ
Mol Cancer Res; 2018 May; 16(5):805-812. PubMed ID: 29523759
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients.
Fang B; Wei Y; Zeng H; Li Y; Chen S; Zhang T; Pan J; Wang B; Wu J; Jin S; Gan H; Hu M; Zhang D; Ye D; Zhu Y
Cancer Immunol Immunother; 2023 Jun; 72(6):1541-1551. PubMed ID: 36522531
[TBL] [Abstract][Full Text] [Related]
28. Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
Xiao X; Dong D; He W; Song L; Wang Q; Yue J; Xie L
Gynecol Oncol; 2018 Apr; 149(1):146-154. PubMed ID: 29496294
[TBL] [Abstract][Full Text] [Related]
29. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
[TBL] [Abstract][Full Text] [Related]
30. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
[TBL] [Abstract][Full Text] [Related]
31. DNA mismatch repair in cancer.
Baretti M; Le DT
Pharmacol Ther; 2018 Sep; 189():45-62. PubMed ID: 29669262
[TBL] [Abstract][Full Text] [Related]
32. Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer.
Burger M; Denzinger S; Hammerschmied CG; Tannapfel A; Obermann EC; Wieland WF; Hartmann A; Stoehr R
J Mol Med (Berl); 2006 Oct; 84(10):833-41. PubMed ID: 16924473
[TBL] [Abstract][Full Text] [Related]
33. No Evidence of Microsatellite Instability and Loss of Mismatch-Repair-Protein Expression in Squamous Cell Carcinoma of the Penis.
Stoehr R; Wendler O; Giedl J; Gaisa NT; Richter G; Campean V; Burger M; Wullich B; Bertz S; Hartmann A
Pathobiology; 2019; 86(2-3):145-151. PubMed ID: 30650417
[TBL] [Abstract][Full Text] [Related]
34. Identification of targets for prostate cancer immunotherapy.
Papanicolau-Sengos A; Yang Y; Pabla S; Lenzo FL; Kato S; Kurzrock R; DePietro P; Nesline M; Conroy J; Glenn S; Chatta G; Morrison C
Prostate; 2019 Apr; 79(5):498-505. PubMed ID: 30614027
[TBL] [Abstract][Full Text] [Related]
35. A Low Tumor Mutational Burden and
Chida K; Kawazoe A; Kawazu M; Suzuki T; Nakamura Y; Nakatsura T; Kuwata T; Ueno T; Kuboki Y; Kotani D; Kojima T; Taniguchi H; Mano H; Ikeda M; Shitara K; Endo I; Yoshino T
Clin Cancer Res; 2021 Jul; 27(13):3714-3724. PubMed ID: 33926917
[TBL] [Abstract][Full Text] [Related]
36. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
Cohen R; Pudlarz T; Garcia-Larnicol ML; Vernerey D; Dray X; Clavel L; Jary M; Piessen G; Zaanan A; Aparicio T; Louvet C; Tournigand C; Chibaudel B; Tougeron D; Guimbaud R; Benouna J; Adenis A; Sokol H; Borg C; Duval A; Svrcek M; André T
Bull Cancer; 2020 Apr; 107(4):438-446. PubMed ID: 32057467
[TBL] [Abstract][Full Text] [Related]
37. Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
Fanale D; Corsini LR; Scalia R; Brando C; Cucinella A; Madonia G; Dimino A; Filorizzo C; Barraco N; Bono M; Fiorino A; Magrin L; Sciacchitano R; Perez A; Russo TDB; Pantuso G; Russo A; Bazan V
Crit Rev Oncol Hematol; 2022 Feb; 170():103597. PubMed ID: 35033663
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Lupinacci RM; Goloudina A; Buhard O; Bachet JB; Maréchal R; Demetter P; Cros J; Bardier-Dupas A; Collura A; Cervera P; Scriva A; Dumont S; Hammel P; Sauvanet A; Louvet C; Delpéro JR; Paye F; Vaillant JC; André T; Closset J; Emile JF; Van Laethem JL; Jonchère V; Abd Alsamad I; Antoine M; Rodenas A; Fléjou JF; Dusetti N; Iovanna J; Duval A; Svrcek M
Gastroenterology; 2018 Mar; 154(4):1061-1065. PubMed ID: 29158190
[TBL] [Abstract][Full Text] [Related]
40. Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair-Deficient Colorectal Cancer.
Li J; Hu H; Qin G; Bai F; Wu X; Ke H; Zhang J; Xie Y; Wu Z; Fu Y; Zheng H; Gong L; Xie Z; Deng Y
Clin Cancer Res; 2024 Jan; 30(2):368-378. PubMed ID: 37906636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
